Wednesday, July 1, 2026

Summary

An 11-year-old boy in Canada died from rabies after exposure to a bat, a case that underscores how a single missed or delayed post-exposure response can be fatal. Human rabies remains rare in Canada, with 28 deaths recorded since 1924.

Why it matters

Rabies is almost always fatal once symptoms begin, so systems that speed post-exposure treatment after bat encounters directly determine who lives.

Summary

New research suggests adults with obesity over 40 now control blood pressure and cholesterol at rates comparable to healthy-weight peers, largely coinciding with widespread use of statins and antihypertensives. The same convergence is not seen in younger adults with obesity, who still show elevated cardiometabolic risk.

Why it matters

If common drugs are neutralizing key obesity-related risk markers after 40, prevention and reimbursement strategies will increasingly hinge on earlier detection and treatment in younger adults where the risk gap persists.

Summary

The FDA approved Orca Bio’s engineered T cell therapy for people with blood cancers undergoing stem cell transplants. The product is designed to lower the risk of severe graft-versus-host disease, a potentially debilitating immune complication.

Why it matters

Lowering graft-versus-host disease risk could expand access to curative transplants and reset the commercial stakes in cell therapies that support, not replace, standard cancer treatment.

Summary

The FDA rejected Galderma’s Botox rival Relfydess, triggering the company’s steepest share drop in more than a year. The decision blocks a near-term US launch for a product positioned to compete in the neuromodulator aesthetics market.

Why it matters

A US regulatory setback can reset growth expectations in a high-margin aesthetics category where timing and physician adoption drive durable market share.